Celcuity CELC Increase Decrease In Accrued Clinical Trial Costs
Increase Decrease In Accrued Clinical Trial Costs at other companies
Other financials
Where this comes from
Reported directly by Celcuity in its filing.
Tagged under the XBRL concept CELC:IncreaseDecreaseInAccruedClinicalTrialCosts.
The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celcuity's increase decrease in accrued clinical trial costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celcuity's increase decrease in accrued clinical trial costs?
- Celcuity (CELC) reported increase decrease in accrued clinical trial costs of -$8.06M in Q1 2026.
- How has Celcuity's increase decrease in accrued clinical trial costs changed year-over-year?
- Celcuity's increase decrease in accrued clinical trial costs decreased by 635.6% year-over-year, from $1.5M to -$8.06M.
- What does increase decrease in accrued clinical trial costs mean?
- Tracks the change in liabilities related to ongoing clinical research and development activities that have been incurred but not yet paid. This is a vital indicator for biotechnology companies to monitor the cash burn rate associated with specific trial milestones.